Aurinia Pharmaceuticals Inc $AUPH Shares Bought by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. raised its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 24.1% during the 2nd quarter, Holdings Channel reports. The firm owned 933,862 shares of the biotechnology company’s stock after buying an additional 181,093 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Aurinia Pharmaceuticals were worth $7,910,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. MAI Capital Management acquired a new stake in Aurinia Pharmaceuticals in the 1st quarter valued at $39,000. Xponance Inc. purchased a new position in Aurinia Pharmaceuticals during the first quarter valued at $82,000. Kazazian Asset Management LLC purchased a new position in Aurinia Pharmaceuticals during the first quarter valued at $84,000. Mackenzie Financial Corp acquired a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at about $86,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth about $92,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on AUPH. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $15.00 price target (up from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 5th. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Bloom Burton downgraded Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Jefferies Financial Group upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the stock from $10.00 to $21.00 in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Aurinia Pharmaceuticals has an average rating of “Hold” and an average price target of $17.67.

Aurinia Pharmaceuticals Price Performance

AUPH stock opened at $15.22 on Friday. Aurinia Pharmaceuticals Inc has a 1 year low of $6.55 and a 1 year high of $16.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. The firm has a market capitalization of $2.01 billion, a PE ratio of 35.40 and a beta of 1.30. The business has a 50 day simple moving average of $12.54 and a 200-day simple moving average of $10.37.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.07. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The firm had revenue of $73.47 million for the quarter, compared to the consensus estimate of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.